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ATR Regulates Fragile Site Stability
Common fragile sites are normally stable in culturedAnne M. Casper,1 Paul Nghiem,2,3,5 Martin F. Arlt,1
and Thomas W. Glover1,4 human cells. However, following induction with replica-
1Department of Human Genetics tion inhibitors, these sites are “hot spots” for increased
University of Michigan sister chromatid exchanges (SCE), translocations, and
Ann Arbor, Michigan 48109 deletions (Glover and Stein, 1987, 1988; Wang et al.,
2 Department of Chemistry and Chemical Biology 1997). They are preferred sites of plasmid integration
Howard Hughes Medical Institute (Rassool et al., 1991) and may be favored targets for
Harvard University DNA virus integration in vivo (Thorland et al., 2000; Wilke
Cambridge, Massachusetts 02138 et al., 1996). Fragile sites may also play a role in some
3 Cutaneous Oncology Unit gene amplification events, both in vitro and in tumor
Dana-Farber Cancer Institute cells, by triggering a breakage-fusion-bridge cycle (Co-
Boston, Massachusetts 02115 quelle et al., 1997). All of these chromosomal alterations
are preceded by a DNA double-strand (DS) break, lead-
ing to the conclusion that DS breaks are sometimes
Summary associated with fragile site expression.
Five fragile sites have been cloned and characterized
Conditions that partially inhibit DNA replication induce and have been found to extend over hundreds of kilo-
expression of common fragile sites. These sites form bases, with gaps or breaks on metaphase chromosomes
gaps and breaks on metaphase chromosomes and occurring throughout these regions (Glover, 1998;
are deleted and rearranged in many tumors. Yet, the Huebner and Croce, 2001). Numerous studies have
mechanism of fragile site expression has been elusive. shown that these sites are unstable in tumor cells. For
We demonstrate that the replication checkpoint ki- example, FHIT, the gene spanning FRA3B, is often re-
nase ATR, but not ATM, is critical for maintenance of arranged or partially deleted in many tumors, including
fragile site stability. ATR deficiency results in fragile lung, breast, ovarian, cervical, and esophageal (Druck
site expression with and without addition of replication et al., 1997; Michael et al., 1997; Mimori et al., 1999).
inhibitors. Thus, we propose that fragile sites are un- Investigation of chromosome 3 homologs from tumor
replicated chromosomal regions resulting from stalled cell lines showed multiple variable deletions within
forks that escape the ATR replication checkpoint. FRA3B, suggesting ongoing instability in the region
These findings have important implications for under- (Corbin et al., 2002). WWOX, the gene at FRA16D, shows
standing both the mechanism of fragile site instability
loss of heterozygosity and deletions in various cancers,
and the consequences of stalled replication in mam-
as do FRA7G, FRA7H, and FRAXB (Arlt et al., 2002;
malian cells.
Huang et al., 1999; Paige et al., 2000; Ried et al., 2000).
Through functional studies, both FHIT and WWOX have
Introduction
been identified as tumor suppressors (Bednarek et al.,
2001; Dumon et al., 2001; Paige et al., 2001). However,
Common fragile sites are loci that exhibit gaps and
the genes identified at FRAXB are not involved in tumor
breaks on metaphase chromosomes of cells that have
progression, indicating that fragile site instability in tu-been cultured under conditions of replicative stress,
mors is not driven solely by associated gene function.such as folate deficiency or treatment with aphidicolin
All of these results support the hypothesis that fragile(Glover et al., 1984). Unlike rare fragile sites, which result
sites are involved in chromosome rearrangements infrom expanded di- or trinucleotide repeat mutation
cancer.(Sutherland et al., 1998), common fragile sites do not
Determining the mechanism of common fragile sitecontain such repeats and are a normal component of
expression is important in understanding a normal com-chromosome structure. The exact number of common
ponent of chromosome structure and function and infragile sites that exist is a matter of interpretation, and
understanding the instability found at fragile sites in75 aphidicolin-induced common fragile sites are listed
tumor cells. Beyond the knowledge that partial inhibitionin Genbank. Increasing the stress placed on DNA repli-
of DNA synthesis is involved, little is known about thecation leads to the expression of increasing numbers of
mechanism of common fragile site expression. Se-fragile sites, until replication stops altogether. However,
quence analyses have not readily revealed why the sitesgaps and breaks at just 20 fragile sites represent over
are unstable; however, all fragile sites studied to date80% of all lesions observed in lymphocytes following
are relatively AT-rich (Arlt et al., 2002; Ried et al., 2000;treatment with low doses of aphidicolin (Glover et al.,
Shiraishi et al., 2001) and contain more areas of high1984). FRA3B at 3p14.2 stands out as the most “fragile”
flexibility than non-fragile regions (Mishmar et al., 1998).site in the genome, followed by 16q23 (FRA16D), 6q26
Studies of replication timing at FRA3B have found this(FRA6E), 7q31.2 (FRA7G), and Xp22.3 (FRAXB).
site to be late replicating (Le Beau et al., 1998; Wang et
al., 1999), as had previously been shown for the fragile4 Correspondence: glover@umich.edu
X site (FRAXA) (Hansen et al., 1997). Following addition5 Present address: Cutaneous Biology Center, Massachusetts Gen-
eral Hospital, Charlestown, MA 02129. of aphidicolin, FRA3B replicates even later, and in some
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cells may remain unreplicated in G2. Replication timing Results
at FRA7H has also been studied and a detailed analysis
indicated significant differences in the replication timing 2-AP, an Inhibitor of ATM and ATR, Increases
Fragile Site Expressionof adjacent segments with some segments replicating
late in S phase, a pattern that was exaggerated by the We first tested the hypothesis that ATM and ATR have
a role in the maintenance of fragile site stability by in-addition of aphidicolin (Hellman et al., 2000). These re-
sults suggest that late replication may play a role in vestigating the effect of 2-AP, a kinase inhibitor of both
ATM and ATR (Dimitrova and Gilbert, 2000; Sarkaria etfragile site expression.
Based on the occurrence of DNA breaks and chromo- al., 1999), on fragile site expression. Caffeine, which also
inhibits the function of both ATM and ATR (Sarkaria etsome rearrangements at fragile site loci and the possible
role of replication fork stalling at these sites, we hypoth- al., 1999), has previously been observed to enhance
fragile site expression (Glover et al., 1986; Yunis andesized that the S phase and G2/M cellular checkpoint
proteins Ataxia-Telangiectasia Mutated (ATM) and Soreng, 1984), suggesting that these checkpoint pro-
teins could be involved in fragile site recognition or re-Ataxia-Telangiectasia and Rad3-Related (ATR) are in-
volved in fragile site maintenance and stability. Recent pair. Thus, we predicted that 2-AP, like caffeine, would
also increase fragile site expression. We compared thefindings show that ATM and ATR act in distinct but
partially overlapping pathways in response to specific effect of treating human lymphocytes with 2-AP to treat-
ment with caffeine. Metaphase chromosomes were tryp-types of DNA damage during cellular replication (Abra-
ham, 2001; Durocher and Jackson, 2001). ATM has been sin banded to determine whether the chromosomal gaps
and breaks observed after treatment corresponded tostudied in cell lines derived from AT patients and is
activated by DNA DS breaks. Thus, AT cells are sensitive the cytogenetic location of recognized fragile sites. Few
chromosomal gaps or breaks were observed with 2-APto ionizing irradiation but not UV-light (Pincheira et al.,
2001). ATR has been more difficult to study, as knockout alone, but six of the ten total gaps/breaks from two
individuals observed at the 5 mM treatment level weremice die in early embryogenesis, and cells lacking this
protein are inviable within a few cell divisions (Brown at FRA3B (n  50 cells per individual). When 2-AP is
added with aphidicolin, there is a dramatic rise in aver-and Baltimore, 2000). In the past few years, it has been
shown that ATR is required for checkpoint responses age overall chromosomal gaps and breaks that esca-
lates with increasing 2-AP concentrations (Figure 1A).after treatment of cells with UV light and agents that
block replication fork progression, such as hydroxyurea From banded chromosomes, we determined that90%
of the gaps and breaks occurred at recognized fragileand aphidicolin (Cliby et al., 1998; Cortez et al., 2001;
Nghiem et al., 2001) and, more recently, hypoxia (Ham- sites (data not shown). The expression of a specific
fragile site, FRA3B, correlates with these data (Figuremond et al., 2002). A major outcome of ATR deficiency
found with these approaches was extreme chromosome 1B). These results are similar to those observed with
caffeine (Figures 1C and 1D). Thus, both caffeine andfragmentation following treatment of cells with high con-
centrations of aphidicolin or hydroxyurea (Nghiem et al., 2-AP increase the expression levels of common fragile
sites. As caffeine and 2-AP inhibit ATM and ATR, these2001). The current model is that ATM and ATR perform
critical early functions to activate the replication check- data support the hypothesis that one or both of these
protein kinases are involved in the maintenance of fragilepoints in response to DNA DS breaks or stalled replica-
tion forks, respectively. site stability.
We have investigated the role of ATM and ATR in
the maintenance of fragile site stability. We found that
ATM Is Not Required for the Maintenance2-aminopurine (2-AP), an inhibitor of ATM and ATR ki-
of Fragile Site Stabilitynases (Dimitrova and Gilbert, 2000; Sarkaria et al., 1999),
In order to differentiate between the relative contribu-increases fragile site expression. We then used AT cell
tions of ATM and ATR to fragile site stability, we studiedlines to study ATM and three methods to study ATR: (1)
cell lines deficient in either ATM or ATR activity. Wea dominant-negative approach in stably transfected cell
investigated ATM by comparison of fragile site expres-lines; (2) cre-lox mediated ATR deficiency in cell lines
sion in seven AT lymphoblast cell lines to that in fourwith lox P-flanked ATR; and (3) RNAi using siRNA du-
normal control human lymphoblast lines followingplexes directed against ATR. We found that fragile site
aphidicolin treatment. Four of the seven AT lines studiedexpression is unchanged in AT cells, indicating that ATM
have known truncating mutations in the ATM gene (Tela-is not required for the maintenance of fragile site stabil-
tar et al., 1996; Wright et al., 1996), and analysis ofity. In contrast, partial inhibition of ATR caused a 5-
protein expression by Western blot demonstrates thatto 20-fold increase in aphidicolin-induced fragile site
none of the seven AT lines have detectable ATM expres-expression compared to control cells. Furthermore, we
sion (Figure 2A). Following aphidicolin treatment, wefound that fragile sites are expressed in ATR-deficient
found an average of 1.21 gaps and breaks per cell incells without addition of replication inhibitors. These
normal lines, compared to an average of 1.16 gaps andresults demonstrate that the ATR checkpoint pathway
breaks per cell in AT lines (P 0.526) (Figure 2B). Analy-is critical for the maintenance of stability at common
sis of average breaks at FRA3B per cell also indicatedfragile sites. This finding is an important advance in
insignificant differences between normal and AT linesunderstanding the mechanism of fragile site mainte-
(P  0.856) (Figure 2B). These results suggest that thenance in normal cells and chromosome rearrangements
at fragile sites in tumor cells. role of ATM in fragile site expression is negligible.
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Figure 1. 2-Aminopurine Increases Common Fragile Site Expression
(A) Average overall chromosome gaps and breaks per cell in normal human lymphoblasts after aphidicolin and 2-AP treatment (n  50
metaphases).
(B) Total gaps and breaks at FRA3B in normal human lymphoblasts after aphidicolin and 2-AP treatment (n  50 metaphases).
(C) Average overall chromosomal gaps and breaks per cell in normal human lymphoblasts after aphidicolin and caffeine treatment (n  50
metaphases).
(D) Total gaps and breaks at FRA3B in normal human lymphoblasts after aphidicolin and caffeine treatment. (n  50 metaphases). Values
next to plotted lines indicate M aphidicolin treatment.
(A–D) Solid and dashed lines indicate results from two individuals.
ATR Is Critical for the Maintenance breaks in ATR-kd expressing cells. It is known that most
chromosomal gaps and breaks following aphidicolinof Fragile Site Stability
We next studied the role of ATR in fragile site stability. treatment occur at fragile sites (Glover et al., 1984). How-
ever, to verify that the increase in gaps and breaks inAs animals and cells lacking ATR are inviable (Brown
and Baltimore, 2000), we used three methods to over- cells with ATR deficiency is not due to global instability
at random sites, we measured expression at specificcome this problem: (1) a dominant-negative approach
using stable cell lines expressing either ATR-wt or ATR- common fragile sites using FISH approaches with BAC
and YAC probes specific to FRA3B, FRA16D, andkd; (2) cre-lox mediated ATR deficiency using ATRflox/
cell lines allowing for removal of lox-P flanked ATR; and FRA7H. We did not observe typical expression of FRA3B
or FRA16D under any treatment condition, perhaps due(3) RNAi using siRNA duplexes directed against ATR.
We first tested the effect of inducing fragile sites with to rearrangements in this tumor cell line. However, typi-
cal fragile site expression was observed at FRA7H, thusaphidicolin in U2-OS (human osteosarcoma) cells stably
transfected with doxycycline-inducible wild-type (ATR- allowing its analysis. Comparison of breaks and gaps at
this site showed a 10-fold increase in FRA7H expressionwt) or dominant-negative kinase-dead ATR (ATR-kd) ex-
pression constructs (Nghiem et al., 2001). These lines in cells expressing ATR-kd after aphidicolin treatment as
compared to ATR-wt controls, which is in agreement withhad undetectable expression of the FLAG-tagged ATR-
wt and ATR-kd proteins in the absence of doxycycline. our results from total gaps and breaks (Figure 3C).
In a second approach, we inactivated ATR in ATRflox/Dox induction resulted in greatly increased levels of
ATR-wt or ATR-kd as monitored by Western blotting cells. In this cell line, derived from HCT116 (human mis-
match repair-deficient) cells, both alleles of ATR have(Figure 3A). After the addition of aphidicolin, average
overall chromosomal gaps and breaks were increased been stably modified such that one allele is interrupted
by insertion of the neor gene and the other allele contains20-fold in ATR-kd expressing cells, as compared to
ATR-wt expressing cells (Figure 3B). ATR-kd expressing lox P sites flanking exon 2 (Cortez et al., 2001). ATR
expression in ATRflox/ cells is less than half that of thecells were much more sensitive to aphidicolin than ATR-
wt expressing cells. Aphidicolin concentrations that pro- parent HCT116 cells, and adenovirus mediated cre-lox
removal of the remaining allele of ATR results in unde-duce few to no fragile sites in normal cells and cells
expressing ATR-wt result in very high levels of gaps and tectable ATR expression by three days post infection, as
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Figure 2. ATM Deficiency Does Not Affect Common Fragile Site
Expression
(A) Western blot probed with -ATM showing lack of ATM protein
expression in cell lines from AT patients. Non-specific bands indi-
cate protein loading.
(B) Average total chromosomal gaps and breaks per cell and average
gaps and breaks at FRA3B per cell in four normal lymphoblast lines
(UML39, LD2, LD5, and LD12) versus seven AT lymphoblast lines
(GM08436, GM13326, GM01525, GM03189, GM00719, GM03332,
and GM14058); n  50 metaphases for each cell line and condition.
For fragile site induction, 0.4 M aphidicolin was added 24 hr before
harvesting. APH: aphidicolin.
observed by Western blots (Figure 4). PCR with primers
flanking the lox P sites also indicated the expected dele-
tion product following AdCre1 infection (data not
shown). We were able to achieve infection levels of 90%
in this line as monitored by infection with adenovirus-
expressing GFP (data not shown). We found that aver- Figure 3. Cells Expressing ATR-kd Have Increased Common Fragile
age overall chromosomal gaps and breaks were in- Site Expression
creased in lines lacking ATR expression, as compared (A) Western blot probed first with -ATR, then stripped and reprobed
to the parent line after treatment with aphidicolin (Figure with -FLAG antibodies, showing specific, highly inducible expres-
sion of FLAG-tagged ATR-wt or ATR-kd in stably transfected U2-4B). This increase was relatively linear with increasing
OS cells. Non-specific bands indicate even loading. Whole-cell ly-aphidicolin treatment levels. Compared to controls,
sate was collected 24 hr after dox induction.fragile site expression was increased 5-fold in floxed
(B) Average overall chromosomal gaps and breaks in ATR-wt or
cells after treatment with 0.05M aphidicolin, while after ATR-kd expressing cells; n  50 metaphases for each condition.
treatment with 0.1M aphidicolin, fragile site expression (C) Frequency of FRA7H expression in ATR-wt or ATR-kd expressing
was increased 10-fold (Figures 4B and 4D). At the 0.1 cells; n  100 hybridization signals for each condition. Induction of
ATR-wt or ATR-kd expression was achieved by addition of 1 g/mlM aphidicolin treatment level, there was a wide range
doxycycline 48 hr before harvest. For fragile site induction, 0.05 Mof fragile site expression, with a few cells expressing
aphidicolin was added 24 hr before harvest.so many gaps and breaks that chromosomes had a
shattered appearance, similar to the previously ob-
served premature chromatin condensation (PCC) phe- used as a third independent method to explore the rela-
tionship between ATR function and the maintenance ofnotype reported in ATR deficient cells that had been
treated with much higher aphidicolin concentrations fragile site stability. Successful employment of RNAi in
mammalian cells has recently been achieved through(Nghiem et al., 2001). Similar to the overall gaps and
breaks, cells lacking ATR had a 7- to 8-fold increase in the use of short interfering RNAs (siRNAs) (Elbashir et
al., 2001; Harborth et al., 2001). These siRNAs are du-FRA3B and FRA16D expression as measured by FISH
using probes specific to these fragile sites (Figure 4C). plexes of 21 nt RNAs with 2 nt 3 overhangs, matching
unique sequence in the 5 region of the targeted mRNA.RNA interference (RNAi) directed against ATR was
ATR Deficiency Induces Fragile Sites
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Figure 4. Cells with Cre-Lox Inactivation of ATR Have Increased Common Fragile Site Expression
(A) Western blot probed with -ATR shows severely reduced ATR expression in ATRflox/ cells as compared to HCT116 cells and complete
loss of ATR expression in ATRflox/ cells 72 hr after AdCre1 infection. Non-specific bands indicate even loading. Whole-cell lysate was collected
72 hr after AdCre1 infection.
(B) Average overall chromosomal gaps and breaks in HCT116 cells compared to ATRflox/ cells; n  50 metaphases for each condition. As
indicated on the graph, *6 of 50, **7 of 50, and ***29 of 50 metaphases analyzed had a shattered appearance similar to the PCC phenotype
(Nghiem et al., 2001) and thus were not included in calculation of average breaks per cell. Cre-lox inactivation of ATR was achieved by AdCre1
infection 96 hr before harvest. For fragile site induction, 0.05 M or 0.1 M aphidicolin was added 24 hr before harvest.
(C) Frequency of FRA3B and FRA16D expression in HCT116 cells compared to ATRflox/ cells; n  at least 50 hybridizations for each condition.
For fragile site induction, 0.05 M aphidicolin was added 24 hr before harvest.
(D) Representative metaphases of ATRflox/ cells after cre-lox inactivation of ATR and addition of increasing concentrations of aphidicolin. See
text for details. Cre-lox inactivation of ATR was achieved by AdCre1 infection 96 hr before harvest.
Two siRNA sequences directed against ATR (siRNA-1 iting ATR protein levels than siRNA-1. No decrease in
ATR protein level was observed after transfection withand siRNA-2) and matching single-stranded RNA sense
controls were constructed. These RNAs were trans- single-stranded, sense control RNAs (Figure 5A). In
agreement with the Western blot data, we found thatfected into HCT116 and HeLa cells. Transfection levels
of a fluorescently conjugated (Cy-3) control RNA were the increase in gaps and breaks in cells transfected
with siRNA-1 was not as pronounced as the increase95% and 90% in these lines, respectively (data not
shown). Western blots from cells two days after trans- observed in cells transfected with siRNA-2. Compared
to controls, gaps and breaks increased 3-fold and 9-foldfection indicate that siRNA-2 is more efficient at inhib-
Cell
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Figure 5. Cells with siRNA Inactivation of ATR Have Increased Common Fragile Site Expression
(A) Western blot probed with -ATR showing reduced ATR expression in HCT116 and HeLa cells transfected with siRNA-1 or siRNA-2. Whole-
cell lysate was collected 24 hr after transfection.
(B) Average overall chromosomal gaps and breaks in HeLa cells after transfection with siRNA-1, siRNA-2, or control RNAs; n  20 metaphases
for each condition. Inactivation of ATR was achieved by siRNA transfection 48 hr before harvest. Fragile site induction was achieved by
addition of 0.3 M aphidicolin 24 hr before harvest.
(C) Average overall chromosomal gaps and breaks in HCT116 cells after transfection with siRNA-1, siRNA-2, or control RNAs; n 20 metaphases
for each condition. Inactivation of ATR was achieved by siRNA transfection 48 hr before harvest. Fragile site induction was achieved by
addition 0.3 M aphidicolin 24 hr before harvest.
(D) Frequency of FRA3B and FRA16D expression in HeLa cells after transfection with siRNA-1, siRNA-2, or control RNAs; n  at least 50
hybridizations for each condition. Inactivation of ATR was achieved by siRNA transfection 48 hr before harvest. Fragile site induction was
achieved by addition of 0.3 M aphidicolin 24 hr before harvest.
(E) Frequency of FRA3B and FRA16D expression in HCT116 cells after transfection with siRNA-1, siRNA-2, or control RNAs; n  at least 50
hybridizations for each condition. Inactivation of ATR was achieved by siRNA transfection 48 hr before harvest. Fragile site induction was
achieved by addition of 0.3 M aphidicolin 24 hr before harvest.
(F) Partial metaphase showing an example of FISH on a siRNA-1 transfected HCT116 cell after 0.3 M aphidicolin treatment. FRA3B is indicated
by hybridization with YAC probe 850A6 (green); one homolog is broken. FRA16D is indicated by hybridization with BAC probe 264L1 (red);
one homolog is broken. The G-banding karyotype of HCT116 cells is 45,X,-Y,t(8;16)(q13;p13), add (10q), add (18p) (Masramon et al., 2000).
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Table 1A. Fragile Sites Are Observed in ATR-kd Expressing Cells without Prior Aphidicolin Induction
Avg. gaps % of total breaks
Breaks per cell % FRA7H loci attributable to
Cell line Treatment (n  50 cells) with a break FRA7H
ATR-wt  dox APH 0.26 1% (1/100) 7.7%
 dox APH 0.08 0% (0/100) 0%
 dox APH 0.08 0% (0/100) 0%
ATR-kd  dox APH 9.16 26% (26/100) 5.7%
 dox APH 2.86 7% (7/100) 4.7%
 dox APH 0.10 1% (1/100) 20%
APH, aphidicolin (0.05 m)
in aphidicolin-treated HeLa cells transfected with in aphidicolin-treated cells (5.7%) (Table 1A). In ATRflox/
cells, ATR was inactivated by adenovirus-mediated cresiRNA1 and siRNA2, respectively (Figure 5B). Data from
transfected HCT116 cells showed a similar pattern, with expression four days prior to harvest, and no aphidicolin
was added to cultures. We observed an 18-fold increasegaps and breaks increased 6-fold and 8-fold in siRNA1
and siRNA2 transfected cells, respectively (Figure 5C). in total gaps and breaks in cells lacking ATR, as com-
pared to control cells, and FISH with probes to FRA3BFISH on both HCT116 and HeLa cells with probes to
FRA3B and FRA16D indicated a similar increase in gaps and FRA16D indicated that these sites are also broken
more often in ATR null cells (Table 1B).and breaks at these specific loci in cells transfected
with siRNA, as compared to control transfections (Fig-
ures 5D, 5E, and 5F). Discussion
We have demonstrated that ATR, but not ATM, is criticalFragile Sites Are Observed in ATR-Deficient Cells
without Aphidicolin Induction for the maintenance of common fragile site stability. We
found that 2-AP, like caffeine, increases aphidicolin-Our results, together with the known essential replica-
tion checkpoint role of ATR, suggest that replication induced fragile site expression. Both 2-AP and caffeine
inhibit the kinase function of ATM and ATR. Thus, thesestalling at fragile sites could be a normal occurrence
during cellular replication. Thus, we hypothesized that results support the hypothesis that these cellular check-
point proteins have a role in the maintenance of fragilefragile site expression would be observed in ATR-defi-
cient cells after extended culture times, even without site stability. We then differentiated between the relative
contributions of ATM and ATR. Using AT cell lines, weaphidicolin induction. We tested this hypothesis in ATR-
kd and ATR-wt expressing cells and in ATRflox/ cells. determined that ATM deficiency has no effect on fragile
site expression. As the ATM/CHK2 pathway is knownDox induction of ATR-wt and ATR-kd expression was
maintained for five days before harvest, and no aphidi- to be necessary for response to DS breaks during S
phase, it is therefore unlikely that DS breaks are a pri-colin was added to cultures. We observed a 30-fold
increase in average chromosomal gaps and breaks in mary cause of fragile site expression, although they can
sometimes occur as a secondary event at these sitesATR-kd expressing cells, as compared to control cells,
and FISH with a probe to FRA7H indicates that the ex- and give rise to chromosomal rearrangements.
We used three independent approaches to study ATR,pression of this fragile site correlates with these data.
Although the total gaps and breaks per cell is greater in including dominant-negative kinase-dead ATR expres-
sion, cre-lox mediated deletion of ATR, and RNAi di-aphidicolin-treated cells, the percentage of total breaks
attributable to FRA7H ATR-kd expressing cells without rected against ATR. Our results from all three ap-
proaches clearly demonstrate that ATR is critical for theaphidicolin treatment (4.7%) is similar to that observed
Table 1B. Fragile Sites Are Observed in ATRflox/ Cells without Prior Aphidicolin Induction
Avg. gaps,
Breaks per cell % FRA3B loci % of total breaks % FRA16D loci % of total breaks
Cell line Treatment (n  50 cells) with a break attributable to FRA3B with a break attributable to FRA16D
HCT116 cre APH 0.46 5% (3/59) 22% 2% (1/50) 9%
cre APH 0.04 - - - -
cre APH 0.04 - - - -
ATRflox/ cre APH 4.5a 35% (22/63) 15.5% 20% (10/50) 8.8%
cre APH 0.73b 4.2% (6/122) 11.5% 1% (2/122) 2.8%
cre APH 0.04 - - - -
a 7 metaphases with shattered chromosomes (similar to PCC phenotype) were not included in count of total gaps/breaks or analysis of fragile
site expression frequency.
b 2 metaphases with shattered chromosomes (similar to PCC phenotype) were not included in count of total gaps/breaks or analysis of fragile
site expression frequency.
APH, aphidicolin (0.05 M)
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maintenance of fragile site stability, as cells with ATR
deficiency are particularly sensitive to aphidicolin-
induced gaps and breaks at fragile sites. Furthermore,
we have found that fragile sites are expressed in cells
with ATR deficiency after several generations without
prior addition of aphidicolin or other replication inhibi-
tors and that ATR deficiency results in gaps and breaks
at fragile sites. These results are important, as they indi-
cate that replication fork stalling that can result in fragile
site expression is a normal occurrence during unchal-
lenged cellular replication, and that ATR recognizes and
responds to stalled or incomplete replication at these
sites. The association of this pathway with the mainte-
nance of genome stability at fragile sites has important
implications for understanding the consequences of
stalled replication in mammalian cells.
ATM and ATR are key members of the intra-S phase,
or replication, and G2/M checkpoint pathways (Abra-
ham, 2001). ATM has been extensively studied, and is
known to respond to DNA DS breaks, such as those
produced by ionizing irradiation (Pincheira et al., 2001).
ATR was identified in 1996 as a member of the PI3K
family (Bentley et al., 1996; Cimprich et al., 1996). Homo-
logs of ATR are present in all eukaryotic cells examined
to date, including budding and fission yeast. Studies of
the related MEC1 in S. cervisiae and rad3 in S. pombe
indicate that these genes are necessary for both the
DNA damage-induced G2 checkpoint and the intra-S
phase checkpoint, which suppresses late origin firing in
the presence of replication inhibitors and prevents cells
Figure 6. Model of Common Fragile Site Expressionfrom entering mitosis in the presence of unreplicated
DNA (Bentley et al., 1996; Santocanale and Diffley, 1998; See text for details.
Weinert et al., 1994). In aphidicolin-arrested CHO cells,
exposure to caffeine or 2-AP results in initiation of repli-
cation at late replicating origins and loss of the ability involve stabilization of existing replicons and inhibition
to reinitiate replication at earlier initiated sites (Dimitrova of late firing origins (Dimitrova and Gilbert, 2000), possi-
and Gilbert, 2000). ATR is likely to be the relevant target bly through recruitment of repair proteins or DNA poly-
of caffeine and 2-AP in this pathway, as shown by recent merases (Lopes et al., 2001; Marchetti et al., 2002).
studies where catalytically inactive versions of ATR re- The current model is that ATM and ATR are critical
sult in loss of S phase checkpoint responses after treat- early activators of cellular checkpoints in response to
ment of mammalian cells with agents that block replica- DNA damage during replication. ATM responds primarily
tion fork progression, such as hydroxyurea, aphidicolin, to DS breaks, and acts at the G1 or later checkpoints
and hypoxia (Cliby et al., 1998; Cortez et al., 2001; Ham- (Abraham, 2001). ATR responds primarily to replicative
mond et al., 2002; Nghiem et al., 2001). Mammalian cells stress, such as caused by aphidicolin and hydroxyurea,
lacking ATR function are also slightly radiosensitive and functions during the intra S and G2/M checkpoints
(Cliby et al., 1998), and chromatin immunoprecipitation to stabilize, and later restart, stalled replication forks
studies in S. cervisiae of ATR homolog Mec1 have shown (Lopes et al., 2001; Tercero and Diffley, 2001), inhibit
this protein to be recruited to a site-specific DS break late origin firing in the presence of stresses (Tercero
at the mating type (MAT) locus (Kondo et al., 2001), and Diffley, 2001), and block cell cycle progression into
suggesting that the role of ATR may be broader than mitosis before replication is complete (Nghiem et al.,
presently indicated. 2001).
Downstream targets of ATR include CHK1, BRCA1,
p53, and H2AX (Liu et al., 2000; Nghiem et al., 2002;
A Model for Common Fragile SitesTibbetts et al., 1999, 2000; Ward and Chen, 2001; Zhao
Our recent data, combined with findings we and othersand Piwnica-Worms, 2001). All of these targets can be
have made over the past twenty years, allow us to createexamined using approaches similar to those used here
a model for common fragile sites (Figure 6). We proposefor ATR. Based on checkpoint function, we propose that
that fragile sites represent single-stranded (unrepli-CHK1 and BRCA1 are likely to be involved in fragile site
cated) regions caused by stalled or collapsed replicationstability. Like ATR, BRCA1 activates CHK1 (Yarden et
forks following partial inhibition of DNA replication. Foral., 2002), which regulates the activity of the CDC25 and
unknown reasons, likely related to sequence and/or rep-WEE1 kinases. These proteins regulate the CDC2/cyclin
lication dynamics, fragile site regions are significantlyB complex, and thus the G2/M checkpoint and progres-
more sensitive to replication fork delay or arrest thansion into mitosis. The exact mechanisms of ATR control
of the S phase checkpoint are unclear, but appear to other regions in the genome. Fragile sites are recognized
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Experimental Proceduresby the S phase and/or G2/M checkpoints in which ATR
plays a key role. However, the appearance of fragile
Cell Culture and Fragile Site Analysissites on metaphase chromosomes in normal cells sug-
Whole blood cultures from normal volunteers were grown in RPMI
gests that some proportion of these lesions can escape 1640 medium 15% FBS with PHA stimulation for 2-AP and caffeine
checkpoint controls. Expressed fragile sites thus sup- treatment. AT lymphoblast cell lines GM08436, GM13326, GM01525,
GM03189, GM00719, GM03332, and GM14058 were obtained fromport classic suggestions that chromosome gaps repre-
Coriell Cell Repositories (Camden, NJ). Cell lines GM08436,sent single-stranded, unreplicated regions. Repair of
GM13326, GM01525, and GM03189 contain identified truncatingsuch structures usually requires DNA-directed homolo-
mutations in the ATM gene (Telatar et al., 1996; Wright et al., 1996).
gous repair. Fragile sites are frequently accompanied Normal control lymphoblast cultures UML39, LD2, LD5, and LD12
by a sister chromatid exchange, thus supporting this were established by Epstein-Barr virus transformation. All lymph-
oblastoid cell lines were diploid. Cells were maintained in RPMIview (Glover and Stein, 1987). Deletions or transloca-
1640 medium  15% FBS. ATR-wt and ATR-kd cells that allowtions at fragile sites can result from DNA DS breaks
doxycycline-inducible expression of FLAG-tagged wild-type orcaused by aberrant processing of Holliday junctions at
dominant-negative kinase-dead ATR were maintained in MEM
damaged forks or illegitimate recombination. Such medium  10% FBS  200 g/ml G418 and 200 g/ml hygromycin
breaks should be recognized by ATM. Thus, the dele- B. Induction of ATR-wt or ATR-kd was achieved by addition of 1
tions seen in tumor cells are proposed to arise from g/ml doxycycline 48 hr prior to harvest. ATRflox/cells, which allow
for cre-lox mediated removal of ATR, were obtained from Dr. Ste-unequal or faulty homologous repair of stalled forks or
phen J. Elledge (Baylor College, Houston, TX) (Cortez et al., 2001)from mutations in the replication checkpoint or associ-
and maintained in MEM medium  10% FBS  200 g/ml G418.ated repair pathways. In this way, deletions at fragile Expression of cre recombinase in these cells was accomplished
sites in tumors are “signatures” of stalled replication through infection with adenovirus AdCre1, which was obtained from
forks. This model predicts that tumor cells with muta- Dr. Frank Graham (McMaster University, Hamilton, Ontario, Canada)
(Anton and Graham, 1995).tions or alterations in replication checkpoint or associ-
Fragile sites were induced by aphidicolin using the concentrationsated homologous repair genes will show increased chro-
and times indicated in the figures and tables. Cells were harvestedmosomal rearrangements at fragile sites.
for chromosome preparations using standard conditions of a 45 min
Common fragile sites appear to be conserved in pri- colcemid treatment (50 ng/ml) followed by an 18 min incubation in
mates (Smeets and van de Klundert, 1990), the mouse 0.075 M KCl at 37C and multiple changes of Carnoy’s fixative (3:1
methanol:acetic acid). Cells were dropped onto slides and slides(Glover et al., 1998; Shiraishi et al., 2001), and likely other
were baked overnight at 60C before Giemsa banding or FISH pro-mammals, suggesting a conserved function such as me-
tocols.diating chromosome replication events during late S
YAC and BAC probes crossing or within fragile site regions were
phase. It has recently been shown that Mec1 deficiency used for FISH analysis. YAC 850A6 was used for FRA3B, BAC264L1
in S. cerevisiae results in non-random chromosome (RP-11) for FRA16D, and BAC 36B6 (RP-11) for FRA7H. Probes
were labeled with biotin-14-dATP or digoxigenin-11-dUTP. Probebreakage within 10 kb “replication slow zones” which
hybridization and immunologic detection were performed accordingoccur, on average, every60 kb in chromosome III (Cha
to standard protocols (Wilke et al., 1996). Biotin-labeled probes wereand Kleckner, 2002). While their size and distribution
detected with avidin-FITC followed by anti-avidin-FITC, and digoxi-
indicates a more simple structure, these regions may be genin-labeled probes were detected with rhodamine-conjugated anti-
functionally analogous to mammalian common fragile body followed by Texas Red anti-goat. For both single-color and
sites. It is of interest in this regard that at least two two-color FISH experiments, chromosomes were counterstained
with DAPI (4, 6-diamidino-2-phenylindole). A Zeiss Axioscopehuman fragile sites have been shown to be late replicat-
epifluorescence microscope and digital image acquisition wereing. However, it is unclear from these studies whether
used for analysis.the late replication observed in fragile site regions is the
result of late origin activation, slow replication initiated
siRNA
at earlier activated origins, replication fork stalling, or a Two siRNA sequences directed against ATR were constructed and
combination of these factors. ordered from Dharmacon Research, Inc. (Lafayette, CO). Both
Replication forks are routinely arrested by a variety siRNAs are duplexes of 21 nt RNAs with a 2 nt 3 overhang; the
siRNA-1 target sequence is AAGCCAAGACAAATTCTGTGT and theof stresses, and checkpoint recognition and the associ-
siRNA-2 target sequence is AACCTCCGTGATGTTGCTTGA. Selec-ated repair of these sites is extremely important in ge-
tion of sequence for these siRNAs was based on Elbashir et al.nome maintenance. Currently, much more is known
(2001) and Harborth et al. (2001) and on guidelines posted on the
about the checkpoint response to DNA DS breaks than Tuschl lab website, http:/a/www.mpibpc.gwdg.de/abteilung/en/
to stalled forks due to replication inhibition. Additionally, 1001/105/sirna.html. Matching single-stranded sense control RNA
sequences were constructed for each of the two siRNAs. Oligofec-prior studies of these checkpoint and repair pathways
tamine (Invitrogen, Carlsbad, CA) was used for transfection of thesehave used high concentrations of replication inhibitors,
RNAs into HCT116 and HeLa cells, according to protocols providedsuch as aphidicolin and hydroxyurea, which would nor-
by Dharmacon. Fragile site expression was induced by the addition
mally completely block replication. Fragile sites are in- of the indicated concentrations of aphidicolin for 24 hr two days
duced at much lower concentrations that only partially posttransfection.
inhibit replication and are more relevant to natural geno-
toxic exposure levels. Thus, fragile site expression pro- Western Blots
5% stacking, 8% resolving polyacrylamide gels were used for pro-vides a novel cytological assay for these checkpoint
tein separation for detection of ATR. 4% stacking, 6% resolvingand associated DNA repair pathways in mammalian
polyacrylamide gels were used for protein separation for detectioncells and can provide insight, not only into the nature
of ATM. 50 g whole-cell lysate was loaded for all lanes. Gels were
of fragile sites, but also the broader consequences of transferred to PVDF membrane, and antibody hybridization and
stalled replication and its repair due to partial inhibition chemiluminescence detection were performed according to stan-
dard protocols. ATR was detected with a rabbit polyclonal antibodyof DNA synthesis.
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generated against amino acids 1–20 of ATR. FLAG-tagged ATR was Druck, T., Hadaczek, P., Fu, T.-B., Ohta, M., Siprashvili, Z., Baffa,
R., Negrini, M., Kastury, K., Veronese, M.L., Rosen, D., et al. (1997).detected with an anti-FLAG M5 antibody from Sigma (St. Louis,
MO). ATM was detected with a rabbit polyclonal antibody from Structure and expression of the human FHIT gene in normal and
tumor cells. Cancer Res. 57, 504–512.Novus Biologicals (Littleton, CO). HRP-conjugated anti-mouse and
anti-rabbit secondary antibodies were obtained from Amersham Dumon, K.R., Ishii, H., Fong, L.Y.Y., Zanesi, N., Fidanza, V., Mancini,
(Piscataway, NJ). R., Vecchione, A., Baffa, R., Trapasso, F., During, M.J., et al. (2001).
FHIT gene therapy prevents tumor development in Fhit-deficient
Statistical Analysis mice. Proc. Natl. Acad. Sci. USA 98, 3346–3351.
For comparisons of average overall gaps and breaks and compari- Durocher, D., and Jackson, S.P. (2001). DNA-PK, ATM and ATR as
sons the frequency of gaps and breaks at specific fragile sites (i.e., sensors of DNA damage: variations on a theme? Curr. Opin. Cell
fragile site expression), the Student’s t test was employed. Biol. 13, 225–231.
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